/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

P

Pablo E. Pérgola

Renal Associates P. A.(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

227

Papers

12.0K

Citations

55

h-index

107

i10-index

Pablo E. Pérgola is an academic researcher from Renal Associates P. A.. The author has contributed to research in topics: Erythropoietin and Anemia Treatment & Dialysis and Renal Disease Management & Hemoglobinopathies and Related Disorders. The author has an h-index of 55, co-authored 193 publications.

ORCID: 0000-0002-5876-894X

Research Topics

Erythropoietin and Anemia Treatment Dialysis and Renal Disease Management Hemoglobinopathies and Related Disorders Iron Metabolism and Disorders Blood Pressure and Hypertension Studies

Papers by this author

works

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial

2013 · The Lancet · 750 citations

https://doi.org/10.1016/s0140-6736(13)60852-1

Oscar Benavente Christopher S. Coffey Robin Conwit Robert G. Hart

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

2021 · The Lancet · 618 citations

https://doi.org/10.1016/s0140-6736(21)00520-1

Paul M. Ridker Matt Devalaraja Florian M.M. Baeres Mads D.M. Engelmann

Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review

2019 · Journal of Medical Economics · 80 citations

https://doi.org/10.1080/13696998.2019.1588738

Bruce Spinowitz Roberto Pecoits‐Filho Wolfgang C. WinkelmayerPablo E. Pérgola

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

2024 · Nephrology Dialysis Transplantation · 63 citations

https://doi.org/10.1093/ndt/gfae132

Hiddo J.L. Heerspink Rajiv Agarwal George L. Bakris David Z.I. Cherney

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy

2018 · Kidney International Reports · 49 citations

https://doi.org/10.1016/j.ekir.2018.07.010

Jeremy D. Gale Steven A. Gilbert Samuel S. Blumenthal Tom Elliott

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

2017 · Kidney International Reports · 47 citations

https://doi.org/10.1016/j.ekir.2017.02.019

Radko Komers Debbie S. Gipson Peter J. Nelson Sharon G. Adler

Research topics

topics

Erythropoietin and Anemia Treatment

Dialysis and Renal Disease Management

Hemoglobinopathies and Related Disorders

Iron Metabolism and Disorders

Blood Pressure and Hypertension Studies

Chat about Author

Papers

Chat

Click to start Chat